Local theatre company, North Shore Players, presents Ben Elton\\\'s first West End success and 2nd play sandwiched between his other stage work \\\'Gasping\\\' and \\\'Popcorn\\\'.
Although first performed in 1991 at London\\\'s Haymarket Theatre, Silly Cow, is still very relevant in today\\\'s celebrity obsessed culture and will keep you either laughing or on the edge of your seat throughout.
This is the first production staged by North Shore Players and is an ideal summer\\\'s evening of entertainment providing the very best of Elton\\\'s comic stage work. Come along, support some local new talent and indulge in some of the funniest theatre you\\\'ll experience this year!
Cast:
• Sidney - Jonathan Callinan
• Doris - Claire Buckley
• Peggy - Claire Wingfield
• Douglas - Matt MacDougall
• Eduardo - Dane Dawson
Director - Lynne Davis
Dates & times: Thursday 7th - Saturday 16th March, 8pm at The Rose Centre, Belmont.
Matinee: Sunday 10th March at 2pm. No Mon performances.
Tickets: $25 adults, $20 seniors and students. Group discounts (10+ seats) available.
Bookings: Ph. Richard at The Rose Centre on 445 9900 or email info@rosecentre.co.nz.
Visit www.rosecentre.co.nz for more information.
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
A new survey from the National Association of Broadcasters (NAB) reveals that two-thirds of young adults have personal experience with mental health problems. Although the overwhelming majority of parents and young adults are supportive of discussing mental illness more openly, more than one-fourth of young adults (28 percent) and one in six parents (16 percent) admit they avoid talking about it.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62650-national-association-of-broadcasters-ok2talk-psa-campaign-on-mental-health
As a new survey conducted online by Harris Interactive on behalf of Nutrisystem among over 3,000 U.S adults in December, indicates more than half of Americans (54 percent) are planning to make New Year’s resolutions to lose weight. Nutrisystem (NASDAQ: NTRI), the leading provider of home-delivered weight loss meal plans, is gearing up to help them succeed in keeping those resolutions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59643-nutrisystem-survey-weight-loss-new-year-s-resolutions
The number of gout patients is rising, with an estimated 8.3 million American adults diagnosed with gout—but only 10 percent of them are being properly treated, according to the Gout & Uric Acid Education Society. To heighten awareness and knowledge about gout and to lead to earlier diagnosis and treatment, the society has released two new comprehensive kits to educate patients and provide consistent information for medical professionals. The release of the Take a Stand on Gout Patient Education Kit and Medical Professional Information Kit coincides with Gout Awareness Day, an annual commemoration on May 22 to call attention to the growing incidence of gout and to enhance knowledge so as to improve patient outcomes. Both kits provide new, substantial information about gout from specialists, who treat gout patients every day.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61805-gout-uric-acid-education-society-take-a-stand-on-gout-new-information-kits
New entertainment integrations and social media initiatives move the “ugly truth” campaign into a new phase this month, further seeding important tobacco-related facts and messages with teens and young adults. The latest advertising campaign from truth – the nation’s largest youth smoking prevention campaign – features its first television ads since 2010, and a host of marketing and digital tools to educate and connect with teens and young people through a range of digital media initiatives and entertainment integrations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62254-truth-campaign-gets-uglier-entertainment-integrations-expand-conversation
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
Doing alright financially? The answer, if you’re 25 to 34 years old, depends on your friends, according to a new survey from the American Institute of CPAs and the Ad Council. They released the results today to coincide with a new series of national public service advertisements and a redesigned website for their Feed the Pig financial literacy campaign.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64083-ad-council-aicpa-young-adult-financial-literacy-campaign
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
